EPHyRaNCT07930728
Evolution of the Treatment of Rare Hypersomnias in a Reference Center Certified Since 2005
StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Ratio of the number of patients who were prescribed this treatment during the year to the number of patients who had at least one consultation at the center during the same year.
Timeframe: For the 1st time for prescriptions from Jan 1, 2005, to Dec 31, 2025. Then, every three years: prescriptions until Dec 31, 2028, Dec 31, 2031, and Dec 31, 2034, in order to take into account marketing of new treatments currently in phase 3
Number of days of treatment
Timeframe: For the 1st time for prescriptions from Jan 1, 2005, to Dec 31, 2025. Then, every three years: prescriptions until Dec 31, 2028, Dec 31, 2031, and Dec 31, 2034, in order to take into account marketing of new treatments currently in phase 3
Secondary (12)
Annual percentage of patients taking at least two treatments for their central hypersomnia.
Number of diagnoses made between 2005 and 2023 that were modified by the new ICSD criteria in 2023.
Percentage of diagnoses made between 2005 and 2023 that were modified by the new ICSD criteria in 2023.
Number of patients with an initial diagnosis of NT2 who were reclassified as NT1 due to the onset of cataplexy.
Percentage of patients with an initial diagnosis of NT2 who were reclassified as NT1 due to the onset of cataplexy.
Show 7 moreShow less
Epworth scale
Wakefulness maintenance tests
Average age of these patients at the onset of cataplexy
Average number of years between initial diagnosis and onset of cataplexy
Average number of years between first symptoms and onset of cataplexy.
Adverse events collected during medical consultations
Effects on other components of the pathologies
Arms and interventions
Central hypersomnia
Patients diagnosed with central hypersomnia
Other: Non applicable
Sites
1 site in 1 country
- Sleep and Vigilance Center, Hôtel-DieuParis, IDF, France